GHRS (GH Research) ROCE % : -17.64% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is GH Research ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GH Research's annualized ROCE % for the quarter that ended in Mar. 2025 was -17.64%.

GH Research ROCE % Historical Data

The historical data trend for GH Research's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research ROCE % Chart

GH Research Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-14.70

-6.50

-8.52

-15.14

-19.51

GH Research Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-14.24	-20.25	-24.89	-19.05	-17.64

GH Research ROCE % Calculation

GH Research's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-38.913	/	( ( (226.3 - 6.701)	+	(188.273 - 8.953) )	/ 2 )
	=	-38.913	/	( (219.599	+	179.32)	/ 2 )
	=	-38.913	/	199.4595
	=	-19.51 %

GH Research's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-43.208	/	( ( (188.273 - 8.953)	+	(320.454 - 9.918) )	/ 2 )
	=	-43.208	/	( ( 179.32	+	310.536 )	/ 2 )
	=	-43.208	/	244.928
	=	-17.64 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

GH Research (NAS:GHRS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GH Research ROCE % Related Terms

Thank you for viewing the detailed overview of GH Research's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GH Research Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1KA:Germany

Address

Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95

Website

https://www.ghres.com

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.